JP2010510236A - 安定化させたｍａｍｌペプチドおよびその使用法 - Google Patents

安定化させたｍａｍｌペプチドおよびその使用法 Download PDF

Info

Publication number
JP2010510236A
JP2010510236A JP2009537371A JP2009537371A JP2010510236A JP 2010510236 A JP2010510236 A JP 2010510236A JP 2009537371 A JP2009537371 A JP 2009537371A JP 2009537371 A JP2009537371 A JP 2009537371A JP 2010510236 A JP2010510236 A JP 2010510236A
Authority
JP
Japan
Prior art keywords
polypeptide
alkyl
modified polypeptide
independently
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009537371A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010510236A5 (enExample
Inventor
ジェームス ブラドナー
レイモンド モラリング
グレゴリー エル． バーダイン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of JP2010510236A publication Critical patent/JP2010510236A/ja
Publication of JP2010510236A5 publication Critical patent/JP2010510236A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2009537371A 2006-11-15 2007-11-15 安定化させたｍａｍｌペプチドおよびその使用法 Pending JP2010510236A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85937906P 2006-11-15 2006-11-15
PCT/US2007/084838 WO2008061192A2 (en) 2006-11-15 2007-11-15 Stabilized maml peptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014007579A Division JP2014114298A (ja) 2006-11-15 2014-01-20 安定化させたｍａｍｌペプチドおよびその使用法

Publications (2)

Publication Number Publication Date
JP2010510236A true JP2010510236A (ja) 2010-04-02
JP2010510236A5 JP2010510236A5 (enExample) 2011-01-27

Family

ID=39402481

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009537371A Pending JP2010510236A (ja) 2006-11-15 2007-11-15 安定化させたｍａｍｌペプチドおよびその使用法
JP2014007579A Pending JP2014114298A (ja) 2006-11-15 2014-01-20 安定化させたｍａｍｌペプチドおよびその使用法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014007579A Pending JP2014114298A (ja) 2006-11-15 2014-01-20 安定化させたｍａｍｌペプチドおよびその使用法

Country Status (6)

Country Link
US (1) US9074009B2 (enExample)
EP (3) EP2997973A1 (enExample)
JP (2) JP2010510236A (enExample)
AU (1) AU2007319193A1 (enExample)
CA (1) CA2669696A1 (enExample)
WO (1) WO2008061192A2 (enExample)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014520120A (ja) * 2011-06-17 2014-08-21 プレジデント アンド フェローズ オブ ハーバード カレッジ 安定化した変異型ｍａｍｌペプチドおよびその使用
JP2016519059A (ja) * 2013-03-13 2016-06-30 プレジデント アンド フェローズ オブ ハーバード カレッジ ステープルドおよびステッチドポリペプチドならびにその使用
US9951099B2 (en) 1999-05-18 2018-04-24 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10202431B2 (en) 2007-01-31 2019-02-12 Aileron Therapeutics, Inc. Stabilized P53 peptides and uses thereof
US10213477B2 (en) 2012-02-15 2019-02-26 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10227380B2 (en) 2012-02-15 2019-03-12 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US10227390B2 (en) 2013-06-14 2019-03-12 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
US10246491B2 (en) 2013-03-06 2019-04-02 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating HIF1alpha
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10301351B2 (en) 2007-03-28 2019-05-28 President And Fellows Of Harvard College Stitched polypeptides
US10308699B2 (en) 2011-10-18 2019-06-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10471120B2 (en) 2014-09-24 2019-11-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US11198713B2 (en) 2017-09-07 2021-12-14 Fog Pharmaceuticals, Inc. Agents modulating beta-catenin functions and methods thereof

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010510236A (ja) 2006-11-15 2010-04-02 ダナ−ファーバー キャンサー インスティテュート インク． 安定化させたｍａｍｌペプチドおよびその使用法
US7981998B2 (en) * 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
BRPI0720306A2 (pt) * 2006-12-14 2014-02-04 Aileron Therapeutics Inc Sistemas de macrociclização da bis-sufidrila
CA2678941C (en) * 2007-02-23 2018-11-27 Aileron Therapeutics, Inc. Triazole macrocycle systems
US20110144306A1 (en) * 2008-07-23 2011-06-16 President And Fellows Of Harvard College Ligation of stapled polypeptides
WO2010034029A1 (en) * 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN104961795A (zh) 2008-09-22 2015-10-07 爱勒让治疗公司 用于制备纯化的多肽组合物的方法
CN102482336B (zh) * 2008-09-22 2015-05-06 爱勒让治疗公司 拟肽大环化合物
CA2743177A1 (en) 2008-11-24 2010-05-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with improved properties
AU2010204648B2 (en) 2009-01-14 2016-09-01 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
BR112012000867A2 (pt) 2009-07-13 2019-09-24 Harvard College "polipeptídeos bifuncional costurado e uso do mesmo"
JP2013505300A (ja) 2009-09-22 2013-02-14 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
WO2012040459A2 (en) * 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
WO2012174423A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized polypeptides as regulators of rab gtpase function
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
RS61957B1 (sr) 2012-09-26 2021-07-30 Harvard College Uvezani peptidi blokirani prolinom i njihove upotrebe
WO2014055564A1 (en) 2012-10-01 2014-04-10 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
WO2015158810A1 (en) 2014-04-17 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides and uses thereof for reducing cd95-mediated cell motility
EP3145523A4 (en) 2014-05-21 2018-02-21 President and Fellows of Harvard College Ras inhibitory peptides and uses thereof
CN107106642B (zh) 2014-09-24 2021-02-26 艾瑞朗医疗公司 拟肽大环化合物及其制剂
US11155577B2 (en) 2015-06-22 2021-10-26 University Of Utah Research Foundation Thiol-ene based peptide stapling and uses thereof
EP3347372A4 (en) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1
US11034720B2 (en) 2016-07-17 2021-06-15 University Of Utah Research Foundation Thiol-yne based peptide stapling and uses thereof
US20200408746A1 (en) * 2018-03-14 2020-12-31 Dana-Farber Cancer Institute, Inc. Stabilized Peptides for Biomarker Detection
BR112021003113A2 (pt) 2018-08-20 2021-05-11 Fog Pharmaceuticals, Inc. coleções de peptídeos, agentes de peptídeos e métodos de uso dos mesmos

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811515A (en) * 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
WO2005044839A2 (en) * 2003-11-05 2005-05-19 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019176A1 (en) 1992-03-23 1993-09-30 Imperial Cancer Research Technology Limited Leucine zippers
JP2001500475A (ja) 1996-07-12 2001-01-16 マクギル ユニバーシティ 細胞接着を調節するための化合物および方法
US5851775A (en) 1997-03-20 1998-12-22 Johns Hopkins University β-catenin, Tcf-4, and APC interact to prevent cancer
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6277824B1 (en) 1998-07-10 2001-08-21 Adherex Technologies Compounds and methods for modulating adhesion molecule function
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
CA2284459C (en) 1999-10-04 2012-12-11 Neokimia Inc. Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
AU2001231154A1 (en) 2000-01-24 2001-07-31 Adherex Technologies Inc. Peptidomimetic modulators of cell adhesion
US7214488B2 (en) * 2001-07-03 2007-05-08 United States Of America, Represented By The Secretary, Department Of Health And Human Services Detection of MECT1-MAML2 fusion products
US7202332B2 (en) 2004-05-27 2007-04-10 New York University Methods for preparing internally constrained peptides and peptidomimetics
DE102004033312A1 (de) * 2004-07-08 2006-01-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren
US8143228B2 (en) 2004-07-12 2012-03-27 Medical Research Fund Of Tel Aviv Sourasky Medical Center Agents capable of downregulating an MSF-A dependent HIF-1α and use thereof in cancer treatment
JP2010510236A (ja) 2006-11-15 2010-04-02 ダナ−ファーバー キャンサー インスティテュート インク． 安定化させたｍａｍｌペプチドおよびその使用法
BRPI0720306A2 (pt) 2006-12-14 2014-02-04 Aileron Therapeutics Inc Sistemas de macrociclização da bis-sufidrila
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CA2678941C (en) 2007-02-23 2018-11-27 Aileron Therapeutics, Inc. Triazole macrocycle systems
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
CA2710964A1 (en) 2007-12-31 2009-09-11 New York University Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices
CN104474529A (zh) 2008-02-08 2015-04-01 爱勒让治疗公司 治疗性的拟肽大环化合物
US20110144303A1 (en) 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
WO2009126292A2 (en) 2008-04-08 2009-10-15 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
WO2010033879A2 (en) 2008-09-18 2010-03-25 New York University Inhibiting interaction between hif-1a and p300/cbp with hydrogen bond surrogate-based helices
KR101754799B1 (ko) * 2010-03-26 2017-07-07 삼성전자주식회사 화소 회로, 이를 포함하는 디스플레이 장치 및 디스플레이 장치의 구동방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811515A (en) * 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
WO2005044839A2 (en) * 2003-11-05 2005-05-19 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6013007212; Ｃｅｌｌ．　２００６　Ｍａｒ，　Ｖｏｌ．１２４，　Ｎｏ．５，　ｐ．９７３-９８３ *
JPN6013007215; Ｊｏｕｒｎａｌ　ｏｆ　ｔｈｅ　ａｍｅｒｉｃａｎ　ｃｈｅｍｉｃａｌ　ｓｏｃｉｅｔｙ．　１９９７，　Ｖｏｌ．１１９，　Ｎｏ．３，　ｐ．４５５-４６０ *
JPN6013007217; Ｓｃｉｅｎｃｅ．　２００４，　Ｖｏｌ．３０５，　Ｎｏ．５６８９，　ｐ．１４６６-１４７０ *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9951099B2 (en) 1999-05-18 2018-04-24 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US10487110B2 (en) 1999-05-18 2019-11-26 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US10202431B2 (en) 2007-01-31 2019-02-12 Aileron Therapeutics, Inc. Stabilized P53 peptides and uses thereof
US10301351B2 (en) 2007-03-28 2019-05-28 President And Fellows Of Harvard College Stitched polypeptides
JP2014520120A (ja) * 2011-06-17 2014-08-21 プレジデント アンド フェローズ オブ ハーバード カレッジ 安定化した変異型ｍａｍｌペプチドおよびその使用
US10308699B2 (en) 2011-10-18 2019-06-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10213477B2 (en) 2012-02-15 2019-02-26 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10227380B2 (en) 2012-02-15 2019-03-12 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US10246491B2 (en) 2013-03-06 2019-04-02 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating HIF1alpha
JP2019218363A (ja) * 2013-03-13 2019-12-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステープルドおよびステッチドポリペプチドならびにその使用
JP7216414B2 (ja) 2013-03-13 2023-02-01 プレジデント アンド フェローズ オブ ハーバード カレッジ ステープルドおよびステッチドポリペプチドならびにその使用
US12258423B2 (en) 2013-03-13 2025-03-25 President And Fellows Of Harvard College Stapled and stitched polypeptides and uses thereof
US10081654B2 (en) 2013-03-13 2018-09-25 President And Fellows Of Harvard College Stapled and stitched polypeptides and uses thereof
KR102637496B1 (ko) 2013-03-13 2024-02-19 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스테이플드 및 스티치드 폴리펩티드 및 그의 용도
US11332496B2 (en) 2013-03-13 2022-05-17 President And Fellows Of Harvard College Stapled and stitched polypeptides and uses thereof
JP2016519059A (ja) * 2013-03-13 2016-06-30 プレジデント アンド フェローズ オブ ハーバード カレッジ ステープルドおよびステッチドポリペプチドならびにその使用
KR20210076179A (ko) * 2013-03-13 2021-06-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스테이플드 및 스티치드 폴리펩티드 및 그의 용도
US10227390B2 (en) 2013-06-14 2019-03-12 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
US10471120B2 (en) 2014-09-24 2019-11-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US11198713B2 (en) 2017-09-07 2021-12-14 Fog Pharmaceuticals, Inc. Agents modulating beta-catenin functions and methods thereof
US11834482B2 (en) 2017-09-07 2023-12-05 Fog Pharmaceuticals, Inc. Agents modulating beta-catenin functions and methods thereof

Also Published As

Publication number Publication date
JP2014114298A (ja) 2014-06-26
AU2007319193A1 (en) 2008-05-22
EP2489360A1 (en) 2012-08-22
US20100081611A1 (en) 2010-04-01
EP2997973A1 (en) 2016-03-23
WO2008061192A3 (en) 2008-07-10
WO2008061192A2 (en) 2008-05-22
CA2669696A1 (en) 2008-05-22
EP2091552A4 (en) 2010-01-06
EP2091552A2 (en) 2009-08-26
US9074009B2 (en) 2015-07-07

Similar Documents

Publication Publication Date Title
JP2014114298A (ja) 安定化させたｍａｍｌペプチドおよびその使用法
JP5649825B2 (ja) 安定化させたｐ５３ペプチドおよびその使用法
AU2024200512B2 (en) Stabilized peptide-mediated targeted protein degradation
JP2014520120A (ja) 安定化した変異型ｍａｍｌペプチドおよびその使用
JP2014502152A (ja) 癌の治療及び診断
BRPI0807578A2 (pt) macrociclo peptidomimético, composto, kit e métodos para sintetizar um macrociclo peptidomimético
WO2019157131A1 (en) Cell-permeable stapled peptide modules for cellular delivery
JP2012116836A (ja) 安定化させたαヘリックスペプチドおよびその使用法
JP7049989B2 (ja) Ｂｆｌ－１と結合するペプチド
AU2014200485A1 (en) Stabilized maml peptides and uses thereof
AU2013231104B2 (en) Stabilized p53 peptides and uses thereof
AU2016210709A1 (en) Stabilized p53 peptides and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130513

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130819

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140120